Ontology highlight
ABSTRACT:
SUBMITTER: Wang H
PROVIDER: S-EPMC2831206 | biostudies-literature | 2010 Feb
REPOSITORIES: biostudies-literature
Wang Huanchen H Luo Xuan X Ye Mengchun M Hou Jing J Robinson Howard H Ke Hengming H
Journal of medicinal chemistry 20100201 4
PDE9 inhibitors have been studied as therapeutics for treatment of cardiovascular diseases, diabetes, and neurodegenerative disorders. To illustrate the inhibitor selectivity, the crystal structures of the PDE9A catalytic domain in complex with the enantiomers of PDE9 inhibitor 1-(2-chlorophenyl)-6-(3,3,3-trifluoro-2-methylpropyl)-1H-pyrazolo[3,4-d]pyrimidine-4(5H)-one ((R)-BAY73-6691 or (S)-BAY73-6691, 1r or 1s) were determined and mutagenesis was performed. The structures showed that the fluor ...[more]